key: cord-0857227-ygywtjcb
authors: Corti, C.; Curigliano, G.
title: Commentary: SARS-CoV-2 vaccines and cancer patients
date: 2021-01-12
journal: Ann Oncol
DOI: 10.1016/j.annonc.2020.12.019
sha: 22c55550abe9a9dcdb7cca14ce03922b52fd6912
doc_id: 857227
cord_uid: ygywtjcb

nan

Since the first reports of coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection has affected more than 79 million people worldwide, prompting the World Health Organization to declare a public health emergency in late January 2020 and a pandemic in March 2020 [1] . Higher mortality of COVID-19 seems to be related to cancer, but data are inconsistent [2] . Of note, most biological agents and immunotherapy do not seem to increase mortality in this setting [2] .

Although an optimal treatment of COVID-19 remains uncertain, pre-pandemic care will return as soon as an effective vaccine strategy becomes available. To date, 44 vaccine candidates are being evaluated for prevention of COVID-19 in phase I clinical trials, followed by 21 and 18 vaccine candidates investigated in phase 2 and 3 trials, respectively [3] . These include nucleic acid-based vaccines, viral-vector vaccines, inactivated or recombinant protein vaccines [3] . In early-phase trials, numerous vaccines have induced binding antibodies, neutralizing activity, and T cell responses in healthy adults [3] . A few candidates seem to be immunogenic in healthy older individuals, as well [3] .

For people with cancer, immunization recommendations have been developed by the Infectious Diseases Society of America (IDSA). In general, patients receiving chemotherapy or other immunosuppressive agents should not receive live vaccines and should generally not receive inactivated vaccines. Although SARS-CoV-2-specific IgG antibody response does not seem to be different between healthy subjects and cancer patients [4], it is unknown whether an effective immunization will be achieved in this subset of people. In this regard, data about how many individuals with a history of cancer have been involved in all phase 3 vaccine trials are lacking. Yet, eligibility of cancer patients can be deduced from inclusion and exclusion criteria of the trials, since some manufacturers made their full study protocols publicly available [5] . Interestingly, most protocols excluded cancer patients on the basis of conditions that can be summarized in three categories ( Table 1) 

Moreover, sample size estimates were based on the basis of low control event rates (CERs) for some trials, suggesting that ~ 99% of placebo recipients is not expected to develop symptomatic COVID-19 [5] . Understandably, such study designs, with symptomatic COVID-19 of any severity as a primary endpoint, low CER estimates and many interim analyses are justified by the need for fast results rather than focusing on severe disease, amidst a global healthcare emergency [5] . That said, people at higher risk, like cancer patients, that should be sensibly prioritized to receive an approved vaccine, may be underrepresented in ongoing phase 3 clinical trials ( Table 1 ).

In conclusion, manufacturers and investigators should be encouraged to provide real-time data about the characteristics of recruited participants, preferably including clearly identifiable subgroups, like cancer patients, with sample sizes large enough to determine safety and efficacy in these categories as well. 

Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

WHO Draft Landscape of Covid-19 candidate vaccines

History of any